Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo

globenewswire.com
ABT Abbott is mentioned as a top market player in the wearables in pharma & biotech market, indicating its significant presence and involvement in this growing sector. DXCM Dexcom is identified as a key company in the wearables for pharma and biotech market, specifically noted for its role in continuous glucose monitors (CGMs) which are a leading product segment. MASI Masimo is listed as one of the top market players in the wearables sector for pharma and biotech, highlighting its participation in this expanding industry.

Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Wearables in Pharma & Biotech Market by Product, Therapy, Application, End User - Global Forecasts to 2031" has been added to ResearchAndMarkets.com's offering.

The wearables in pharma & biotech market is anticipated to grow significantly, reaching USD 9.97 billion by 2031 from USD 3.98 billion in 2026, with a CAGR of 20.2%.

This expansion is fueled by technological advancements in biosensors, miniaturization, and digitization, alongside rising global digital connectivity. The International Telecommunication Union noted that over 5.4 billion people were internet users in 2023, facilitating the seamless integration of wearable data into cloud environments.

Notably, the All of Us Research Program has recruited over 500,000 participants, some of whom contribute data from wearables, demonstrating the pivotal role of wearables in large-scale biomedical research and precision medicine, supported by increasing RPM and digital care solutions.

In the US, CMS reported a notable rise in reimbursement claims for remote physiological monitoring services post-policy expansion in 2022, indicating widespread adoption of wearable-derived care. Enhanced sensor accuracy and multi-parameter monitoring are enabling wearables to measure clinically significant endpoints, expanding their utility in drug safety and therapeutic studies.

Top market players include Abbott (US), Dexcom, Inc. (US), and Masimo (US), offering in-depth competition analysis with company profiles, and market strategies.

Continuous Glucose Monitors (CGMs) Lead Product Segment

CGMs dominate the product segment, propelled by clinical guideline support, a widening scope of eligible patients, and advanced diabetic management systems. The American Diabetes Association's 2024 Standards of Care recommends CGMs for a broad diabetic population, enlarging the market. Reimbursement schemes through the NHS and FDA approvals for interoperable CGMs have further propelled market expansion.

Pharmaceutical and Biotech Companies Hold Largest Market Share

Pharmaceutical and biotech companies lead the market in terms of share by 2025, utilizing wearable technologies for complex clinical data collection. Research by Tufts Center for the Study of Drug Development reveals that clinical trials now involve over 20 endpoints on average, increasing demand for data collection wearables. Initiatives like the UK Biobank underscore the potential of wearables in pharmaceutical research. These companies are expected to continue their dominance in the market.

Asia Pacific Registers Highest Growth

The Asia Pacific region showcases the highest growth rate in the wearables market. This surge is driven by improvements in digital health infrastructure, an increase in clinical research activities, and a substantial patient base. The WHO attributes a considerable share of the global disease burden to this region. Internet penetration here has surpassed 66-70%, and countries like China and India emerge as clinical trial hubs, incorporating technology to boost trial efficiency. Biobeat expanded into Argentina and Chile via a partnership with Infinity Pharma in September 2024.

Reasons to Buy

Key Attributes:

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/j0w2n0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment